Roivant Sciences (ROIV) Return on Invested Capital (2022 - 2024)
Roivant Sciences' (ROIV) quarterly Return on Invested Capital came in at 0.22% in Q4 2024, up 13.0% YoY from 0.2% in Q1 2024, and up 85.95% on a QoQ basis from 0.12% in Q3 2024.
Roivant Sciences (ROIV) Return on Invested Capital (2022 - 2024) Analysis & Trends
Roivant Sciences (ROIV) has 3 years of Return on Invested Capital data on file, last reported at 0.22% in Q4 2024.
- Quarterly Return on Invested Capital rose 13.0% year-over-year to 0.22% in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 0.22% (up 13.0% YoY) and the FY2024 annual result came in at 0.38%, up 61.0% from the prior year.
- Return on Invested Capital grew to 0.22% in Q4 2024, from 0.12% in the prior quarter.
- In the past five years, Return on Invested Capital ranged from a high of 0.22% in Q4 2024 to a low of 0.51% in Q2 2022.
- A 3-year average of 0.04% and a median of 0.06% in 2023 frame the typical range for Return on Invested Capital.
- The widest YoY moves for Return on Invested Capital: up 44 bps in 2023, down 12 bps in 2023.
- Tracing ROIV's Return on Invested Capital over 3 years: stood at 0.11% in 2022, then jumped by 185 bps to 0.09% in 2023, then jumped by 135 bps to 0.22% in 2024.
- The last three Return on Invested Capital figures came in at 0.22% (Q4 2024), 0.12% (Q3 2024), and 0.1% (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROIC (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 0.04% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -0.17% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 0.00% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 0.00% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.35% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Roivant Sciences | 26.20 Bn | 26.20 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 0.22% |
| Sep 30, 2024 | 0.12% |
| Jun 30, 2024 | 0.10% |
| Dec 31, 2023 | 0.09% |
| Sep 30, 2023 | -0.06% |
| Jun 30, 2023 | -0.07% |
| Dec 31, 2022 | -0.11% |
| Sep 30, 2022 | -0.18% |
| Jun 30, 2022 | -0.51% |